Comment from Anonymous

COMMENT ON DOCKET NO. [FDA-2025-P-6831] RE: Formal Notice of Regulatory Non-Compliance, Material Omission, and Demand for Administrative Stay under 21 C.F.R. § 10.35 I submit this comment in support of the Children’s Health Defense petition. This is a formal evidentiary notice that the FDA is operating in violation of its statutory mandates by permitting the distribution of mRNA-LNP products to populations with a 20-year reproductive horizon without the required germline integrity audits. I. THE EVIDENCE OF SYSTEMIC MISCLASSIFICATION (PHYSICAL IDENTITY) The FDA’s “localized vaccine” narrative is mathematically and physically refuted by the manufacturer’s own internal data. The Citation: Pfizer Study 185350 (2.6.4. Pharmacokinetics Tabulation), Table 1, Page 8. The Fact: LNPs exhibit a 117-fold accumulation in ovarian tissue, reaching a peak concentration of 12.261&mu;g/g within 48 hours. The Law: Under 21 U.S.C. § 352(a)(1), a drug is misbranded if its labeling is “false or misleading.” By omitting the 12.261&mu;g/g ovarian peak from public-facing fact sheets and labels, the FDA has facilitated a Material Omission of a known pharmacokinetic risk. II. THE PATHOLOGICAL CONFIRMATION (RELEVANT RESEARCH) The transition from “accumulation” to “injury” has now been documented. The assumption of biological inertness in the ovaries is scientifically dead. The Citation: Karaman et al. (2025), “Histopathological and Biochemical Evaluation of mRNA-LNP Exposure on Ovarian Reserve,” MDPI Vaccines, 13(4). The Fact: mRNA-LNP exposure in mammalian models is associated with a statistically significant increase in atretic (dying) follicles, a marked reduction in Anti-M&uuml;llerian Hormone (AMH), and the upregulation of Caspase-3 (apoptosis/cell death). The Regulatory Failure: Despite this signal, the FDA has failed to trigger the ICH S5 (R3) “Stage A” reproductive toxicity protocols required for any systemic drug that accumulates in the gonads. III. THE “SPINDLE GAP” AND THE VIOLATION OF THE APA The most critical safety void is the lack of data on oocyte meiotic-spindle integrity. The Risk: Synthetic lipids in the follicular environment at concentrations of >12&mu;g/g pose a mechanical risk to the chromosomal “tug-of-war” (meiosis). The Result: Non-disjunction (chromosomal errors) leading to spontaneous aneuploidy (miscarriages/birth defects). The Law: The FDA’s refusal to mandate these audits in the face of the Pfizer 185350 data is “Arbitrary and Capricious” under the Administrative Procedure Act (5 U.S.C. § 706). The Agency has “entirely failed to consider an important aspect of the problem” (State Farm test). IV. PIERCING THE PREP ACT SHIELD The Agency is hereby on notice: The concealment of Study 185350 while maintaining a “localized” safety claim constitutes Scienter (guilty knowledge). The Law: Under 42 U.S.C. § 247d-6d(c)(1), the immunity of the PREP Act is void in cases of “Willful Misconduct.” * The Tort: Failing to warn of a 12.261&mu;g/g ovarian peak while suppressing meiotic-spindle audits establishes a prima facie case for a Generational Tort. CONCLUSION AND DEMAND The FDA must immediately stay the authorization for all females of reproductive potential and pediatric populations until an In-Vivo Oocyte Meiotic-Spindle Integrity and Aneuploidy Audit is completed. This is a non-discretionary ministerial duty. Failure to act constitutes a Forfeiture of Sovereign Immunity through documented malfeasance. Respectfully, Anonymous EXHIBIT A: Audit 1. PHYSICAL IDENTITY (OVARIAN MAP): Pfizer Study 185350 (FOIA PHMPT v. FDA) confirms systemic LNP distribution to ovaries, peaking at 12.261 &mu;g/g at 48h. Narrative of “localized action” is refuted. Failure to disclose this 117-fold ovarian accumulation constitutes Misbranding under 21 U.S.C. § 352. 2. PATHOLOGICAL SIGNAL (DAMAGE REPORT): Karaman et al. (2025), MDPI Vaccines 13(4) documents significant follicular atresia (egg death), reduced AMH (ovarian reserve marker), and Caspase-3 upregulation post-LNP exposure. The 12.261 &mu;g/g ovarian accumulation is proven pathological, not inert. 3. REGULATORY BYPASS (SPINDLE GAP): Under ICH S5(R3), systemic drugs hitting gonadal tissue require germline audits. FDA bypassed this via “Vaccine” classification. Zero in-vivo data exists proving LNP concentrations of 12 &mu;g/g do not disrupt meiotic-spindle integrity. Spindle interference = chromosomal non-disjunction = spontaneous aneuploidy (miscarriage/birth defects). 4. LEGAL IMPLICATION: FDA possession of Study 185350 since 2020 while skipping spindle audits constitutes Scienter and Willful Misconduct (42 U.S.C. § 247d-6d). Continued distribution to pediatric/reproductive populations is “Arbitrary and Capricious” under the APA (5 U.S.C. 706). DEMAND: Immediate stay of authorization for females <50 pending ICH S5(R3) spindle-integrity audits. Reclassify LNPs as Systemic Therapeutic Carriers.